Cancer Immunotherapy & Monoclonal Antibodies

Overview & Definition

Cancer Immunotherapy represents a major paradigm shift in hematological oncology. Unlike conventional chemotherapy that directly attacks rapidly dividing cells, immunotherapy utilizes engineered proteins, monoclonal antibodies, immune checkpoint inhibitors, and bispecific antibodies to train or direct the patient’s own immune system to target and destroy blood cancer cells.

Types & Classification

Monoclonal Antibodies (mAbs) – laboratory-produced proteins designed to bind specific antigens on tumor cells (e.g., Rituximab targeting CD20 on B-cell lymphomas; Daratumumab targeting CD38 on plasma cells in Multiple Myeloma).
Bispecific T-Cell Engagers (BiTEs) – engineered dual-action antibodies that simultaneously bind tumor antigens and T-cell receptors (e.g., Blinatumomab targeting CD19/CD3, Elranatamab, Epcoritamab).
Immune Checkpoint Inhibitors – agents that block immune-suppressive signaling pathways (PD-1 / PD-L1 inhibitors like Pembrolizumab, Nivolumab) to reactivate exhausted T cells.
Antibody-Drug Conjugates (ADCs) – monoclonal antibodies linked to potent cytotoxic agents (e.g., Brentuximab vedotin targeting CD30 in Hodgkin Lymphoma; Polatuzumab vedotin).
Immunomodulatory Drugs (IMiDs) – agents such as Lenalidomide and Pomalidomide that enhance NK cell and T-cell cytotoxicity in Multiple Myeloma and MDS.

Clinical Indications

Relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) & Follicular Lymphoma
Newly diagnosed and relapsed Multiple Myeloma
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Classical Hodgkin Lymphoma after chemo-relapse
Chronic Lymphocytic Leukemia (CLL) consolidation

Common Symptoms & Warning Signs

⚠️ High-risk blood cancer relapse after standard chemotherapy

⚠️ Persistent lymph node swelling or B-symptoms (fever, night sweats)

⚠️ Infusion-related mild chills or skin rash during antibody administration

Diagnostic Evaluation

Before initiating immunotherapy, precise biomarker verification and immunological staging are performed:

🔍 Flow Cytometry & Immunohistochemistry – confirming target antigen expression (CD20, CD38, CD30, CD19).
🔍 PET-CT Staging Scan – evaluating baseline metabolic tumor burden.
🔍 Serum Quantitative Immunoglobulins & Viral Markers – screening for HBV, HCV, and HIV prior to antibody therapy.
🔍 Organ Function Screening – baseline renal, cardiac, and liver function testing.

Treatment Options & Clinical Management

💊 Outpatient Infusion Suite Administration – intravenous or subcutaneous administration of monoclonal antibodies.
💊 Pre-medication Protocols – routine administration of antihistamines, antipyretics, and corticosteroids to prevent infusion reactions.
💊 Bispecific Antibody Step-up Dosing – inpatient monitoring during initial ramp-up doses to prevent Cytokine Release Syndrome (CRS).
💊 Immune-Related Adverse Event (irAE) Management – prompt identification and management of immune-mediated colitis, pneumonitis, or endocrinopathies.

Frequently Asked Questions

Chemotherapy works by directly killing fast-growing cells throughout the body, which can affect healthy tissue like hair follicles and gut lining. Immunotherapy specifically targets cancer cell surface markers or releases immune system brakes, enabling the patient's own immune cells to attack the tumor with greater precision.

Common side effects include mild infusion-related reactions (fever, chills, rash), temporary fatigue, or lower blood counts. Bispecific antibodies may cause mild Cytokine Release Syndrome (CRS). Most side effects are manageable with preventive medications and close clinical monitoring.